中华临床医师杂志（电子版）
中華臨床醫師雜誌（電子版）
중화림상의사잡지（전자판）
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2013年
19期
8711-8714
,共4页
王世红%张婧%邓巍%黄星原
王世紅%張婧%鄧巍%黃星原
왕세홍%장청%산외%황성원
替考拉宁%肺炎%葡萄球菌,金黄色%去甲万古霉素
替攷拉寧%肺炎%葡萄毬菌,金黃色%去甲萬古黴素
체고랍저%폐염%포도구균,금황색%거갑만고매소
Teicoplanin%Pneumonia%Staphylococcus aureus%Norvancomycin
目的：比较替考拉宁与万古霉素对儿童耐甲氧西林金黄色葡萄球菌（MRSA）感染的临床疗效和副作用。方法对2010年7月至2013年4月本院收治MRSA肺炎患儿共95例进行分析，49例给予替考拉宁（前3 d 10 mg/kg，q12 h，然后10 mg/kg，qd），46例给予万古霉素（20 mg/kg，q12 h）治疗，两组均以14 d为一疗程，统计并比较两种方法的临床效果及副作用。结果结果显示，两组总有效率及两组间细菌清除率差异无统计学意义（P＞0.05），但替考拉宁组在退热、止咳，白细胞及CRP恢复正常时间，住院时间上优于万古霉素组（P＜0.01），副作用明显少于万古霉素组（P＜0.01）。结论替考拉宁与稳可信治疗儿童MRSA肺炎的临床疗效临床疗效均较高，但替考拉宁安全性更好。
目的：比較替攷拉寧與萬古黴素對兒童耐甲氧西林金黃色葡萄毬菌（MRSA）感染的臨床療效和副作用。方法對2010年7月至2013年4月本院收治MRSA肺炎患兒共95例進行分析，49例給予替攷拉寧（前3 d 10 mg/kg，q12 h，然後10 mg/kg，qd），46例給予萬古黴素（20 mg/kg，q12 h）治療，兩組均以14 d為一療程，統計併比較兩種方法的臨床效果及副作用。結果結果顯示，兩組總有效率及兩組間細菌清除率差異無統計學意義（P＞0.05），但替攷拉寧組在退熱、止咳，白細胞及CRP恢複正常時間，住院時間上優于萬古黴素組（P＜0.01），副作用明顯少于萬古黴素組（P＜0.01）。結論替攷拉寧與穩可信治療兒童MRSA肺炎的臨床療效臨床療效均較高，但替攷拉寧安全性更好。
목적：비교체고랍저여만고매소대인동내갑양서림금황색포도구균（MRSA）감염적림상료효화부작용。방법대2010년7월지2013년4월본원수치MRSA폐염환인공95례진행분석，49례급여체고랍저（전3 d 10 mg/kg，q12 h，연후10 mg/kg，qd），46례급여만고매소（20 mg/kg，q12 h）치료，량조균이14 d위일료정，통계병비교량충방법적림상효과급부작용。결과결과현시，량조총유효솔급량조간세균청제솔차이무통계학의의（P＞0.05），단체고랍저조재퇴열、지해，백세포급CRP회복정상시간，주원시간상우우만고매소조（P＜0.01），부작용명현소우만고매소조（P＜0.01）。결론체고랍저여은가신치료인동MRSA폐염적림상료효림상료효균교고，단체고랍저안전성경호。
Objective To compare the therapeutic effect and safety of teicoplanin and vancomycin for the treatment of the patients with staphylococcus pneumonia in children. Methods The open-label control test was performed for 95 patients with pneumonia in our hospital from July 2010 to April 2013, 49 cases were treated with teicoplanin for 10 mg/kg, q12 h for the 3 days, then 10 mg/kg qd per day;46 cases were treated with vancomycin for 20 mg/kg, q12 h, which were all the intravenous drip with 14d a course; the therapeutic effect, bacterial clearance, the incidence rate of the adverse reactions before and after the medication between the two groups were compared. Results The clinical effective rates of teicoplanin and vancomycin for treatment of staphylococcus pneumonia were 95.92%and 91.3%, respectively(P>0.05), the bacterial clearance rates were 97.96%and 95.65%, respectively, the differences were not statistically significant(P>0.05);but the teicoplanin group was superior to the vancomycin group in terms of cooling time, cough disappearance time, the recovery time of white blood cell and c-reactive protein, and the hospitalization days, the difference was statistically significant(P<0.01); the incidence rates of the adverse reactions were 2.05%and 17.39%, the incidence rate of the adverse reactions was lower in the teicoplanin group than in the vancomycin group, the difference was statistically significant(P<0.01). Conclusion Both teicoplanin and vancomycin have a similar clinical efficacy on the treatment of patients with MRSA pneumonia, but the teicoplanin is superior to vancomycin in the safety of clinical medication in children.
